The invention is directed to devices for altering gaseous flow within a lung to improve the expiration cycle of an individual, particularly individuals having Chronic Obstructive Pulmonary Disease (COPD). More particularly, devices are disclosed to produce collateral openings or channels through the airway wall so that expired air is able to pass directly out of the lung tissue to facilitate both the exchange of oxygen ultimately into the blood and/or to decompress hyper-inflated lungs.
The term “Chronic Obstructive Pulmonary Disease” (COPD) is generally used to describe the disorders of emphysema and chronic bronchitis. Previously, COPD was also known as Chronic Obstructive Lung Disease (COLD), Chronic Airflow Obstruction (CAO), or Chronic Airflow Limitation (CAL). Some also consider certain types of asthma to fall under the definition of COPD. Emphysema is characterized by an enlargement of air spaces inside the lung. Hence, emphysema is an anatomic definition and it can only be presumed in a living patient. Chronic bronchitis is characterized by excessive mucus production in the bronchial tree. Chronic bronchitis is a clinical definition and denotes those individuals who meet criteria defining the disease. It is not uncommon for an individual to suffer from both disorders.
In 1995, the American Lung Association (ALA) estimated that between 15-16 million Americans suffered from COPD. The ALA estimated that COPD was the fourth-ranking cause of death in the U.S. The ALA estimates that the rates of emphysema is 7.6 per thousand population, and the rate for chronic bronchitis is 55.7 per thousand population.
Those inflicted with COPD face disabilities due to the limited pulmonary functions. Usually, individuals afflicted by COPD also face loss in muscle strength and an inability to perform common daily activities. Often, those patients desiring treatment for COPD seek a physician at a point where the disease is advanced. Since the damage to the lungs is irreversible, there is little hope of recovery. Most times, the physician cannot reverse the effects of the disease but can only offer treatment and advice to halt the progression of the disease.
To understand the detrimental effects of COPD, the workings of the lungs requires a cursory discussion. The primary function of the lungs is to permit the exchange of two gasses by removing carbon dioxide from venous blood and replacing it with oxygen. Thus, to facilitate this exchange, the lungs provide a blood gas interface. The oxygen and carbon dioxide move between the gas (air) and blood by diffusion. This diffusion is possible since the blood is delivered to one side of the blood-gas interface via small blood vessels (capillaries). The capillaries are wrapped around numerous air sacs called alveoli which function as the blood-gas interface. A typical human lung contains about 300 million alveoli.
The air is brought to the other side of this blood-gas interface by a natural respiratory airway, hereafter referred to as a natural airway or airway, consisting of branching tubes which become narrower, shorter, and more numerous as they penetrate deeper into the lung. Specifically, the airway begins with the trachea which branches into the left and right bronchi which divide into lobar, then segmental bronchi. Ultimately, the branching continues down to the terminal bronchioles which lead to the alveoli. Plates of cartilage may be found as part of the walls throughout most of the airway from the trachea to the bronchi. The cartilage plates become less prevalent as the airways branch. Eventually, in the last generations of the bronchi, the cartilage plates are found only at the branching points. The bronchi and bronchioles may be distinguished as the bronchi lie proximal to the last plate of cartilage found along the airway, while the bronchiole lies distal to the last plate of cartilage. The bronchioles are the smallest airways that do not contain alveoli. The function of the bronchi and bronchioles is to provide conducting airways that lead inspired air to the gas-blood interface. However, these conducting airways do not take part in gas exchange because they do not contain alveoli. Rather, the gas exchange takes place in the alveoli which are found in the distal most end of the airways.
The mechanics of breathing include the lungs, the rib cage, the diaphragm and abdominal wall. During inspiration, inspiratory muscles contract increasing the volume of the chest cavity. As a result of the expansion of the chest cavity, the pleural pressure, the pressure within the chest cavity, becomes sub-atmospheric with respect to the pressure at the airway openings. Consequently, air flows into the lungs causing the lungs to expand. During unforced expiration, the expiratory muscles relax and the lungs begin to recoil and reduce in size. The lungs recoil because they contain elastic fibers that allow for expansion, as the lungs inflate, and relaxation, as the lungs deflate, with each breath. This characteristic is called elastic recoil. The recoil of the lungs causes alveolar pressure to exceed the pressure at airway openings causing air to flow out of the lungs and deflate the lungs. If the lungs' ability to recoil is damaged, the lungs cannot contract and reduce in size from their inflated state. As a result, the lungs cannot evacuate all of the inspired air.
In addition to elastic recoil, the lung's elastic fibers also assist in keeping small airways open during the exhalation cycle. This effect is also known as “tethering” of the airways. Such tethering is desirable since small airways do not contain cartilage that would otherwise provide structural rigidity for these airways. Without tethering, and in the absence of structural rigidity, the small airways collapse during exhalation and prevent air from exiting thereby trapping air in within the lung.
Emphysema is characterized by irreversible biochemical destruction of the alveolar walls that contain the elastic fibers, called elastin, described above. The destruction of the alveolar walls results in a dual problem of reduction of elastic recoil and the loss of tethering of the airways. Unfortunately for the individual suffering from emphysema, these two problems combine to result in extreme hyperinflation (air trapping) of the lung and an inability of the person to exhale. In this situation, the individual will be debilitated since the lungs are unable to perform gas exchange at a satisfactory rate.
One further aspect of alveolar wall destruction is that the airflow between neighboring air sacs, known as collateral ventilation or collateral air flow, is markedly increased as when compared to a healthy lung. While alveolar wall destruction decreases resistance to collateral ventilation, the resulting increased collateral ventilation does not benefit the individual since air is still unable to flow into and out of the lungs. Hence, because this trapped air is rich in CO2, it is of little or no benefit to the individual.
Chronic bronchitis is characterized by excessive mucus production in the bronchial tree. Usually there is a general increase in bulk (hypertrophy) of the large bronchi and chronic inflammatory changes in the small airways. Excessive amounts of mucus are found in the airways and semisolid plugs of this mucus may occlude some small bronchi. Also, the small airways are usually narrowed and show inflammatory changes.
Currently, although there is no cure for COPD, treatment includes bronchodilator drugs, and lung reduction surgery. The bronchodilator drugs relax and widen the air passages thereby reducing the residual volume and increasing gas flow permitting more oxygen to enter the lungs. Yet, bronchodilator drugs are only effective for a short period of time and require repeated application. Moreover, the bronchodilator drugs are only effective in a certain percentage of the population of those diagnosed with COPD. In some cases, patients suffering from COPD are given supplemental oxygen to assist in breathing. Unfortunately, aside from the impracticalities of needing to maintain and transport a source of oxygen for everyday activities, the oxygen is only partially functional and does not eliminate the effects of the COPD. Moreover, patients requiring a supplemental source of oxygen are usually never able to return to functioning without the oxygen.
Lung volume reduction surgery is a procedure which removes portions of the lung that are over-inflated. The improvement to the patient occurs as a portion of the lung that remains has relatively better elastic recoil which allows for reduced airway obstruction. The reduced lung volume also improves the efficiency of the respiratory muscles. However, lung reduction surgery is an extremely traumatic procedure which involves opening the chest and thoracic cavity to remove a portion of the lung. As such, the procedure involves an extended recovery period. Hence, the long term benefits of this surgery are still being evaluated. In any case, it is thought that lung reduction surgery is sought in those cases of emphysema where only a portion of the lung is emphysematous as opposed to the case where the entire lung is emphysematous. In cases where the lung is only partially emphysematous, removal of a portion of emphysematous lung increases the cavity area in which the non-diseased parenchyma may expand and contract. If the entire lung were emphysematous, the parenchyma is less elastic and cannot expand to take advantage of an increased area within the lung cavity.
Both bronchodilator drugs and lung reduction surgery fail to capitalize on the increased collateral ventilation taking place in the diseased lung. There remains a need for a medical procedure that can alleviate some of the problems caused by COPD. There is also a need for a medical procedure that alleviates some of the problems caused by COPD irrespective of whether a portion of the lung, or the entire lung is emphysematous.
The present invention addresses the problems caused by COPD by providing a device configured to create collateral openings through an airway wall which allows expired air to pass directly out of the lung tissue responsible for gas exchange. These collateral openings ultimately decompress hyper inflated lungs and/or facilitate an exchange of oxygen into the blood.
Furthermore, there is also a need for devices that are able to access remote areas of the body to provide dual functions of locating an acceptable site for removal or cutting of tissue and then removing or cutting the tissue without having to reposition the device. Such a need is evident in dynamically moving environments (e.g., the lungs) where repositioning of a device to find the original target site may be difficult.
Doppler ultrasound is an effective means to determine the presence or absence of a blood vessel within tissue. It is known that sound waves at ultrasonic frequencies travel through tissue and reflect off of objects/interfaces where density gradients exist. In such a case, the reflected signal and the transmitted signal will have the same frequency. Alternatively, in the case where the signal is reflected from the blood cells moving through a blood vessel, the reflected signal will have a shift in frequency from the transmitted signal. This shift is known as a Doppler shift. However, since the characteristics of components used to detect a Doppler shift vary from characteristics of components used to cut or remove tissue, it is difficult to cut or remove tissue in precisely the same location and immediately after detection has taken place. It is usually required that the component or device used to detect any Doppler shift first must be moved to allow a second component or device to cut or remove the tissue at the same precise location. For instance, if a device uses energy to create an opening or ablate tissue, the energy delivery components may not have acceptable characteristics to function as Doppler components. Furthermore, the process of delivering energy through the device may undesirably impact any Doppler components.
When using Doppler in tissue it is noted that the acoustic impedance of the ultrasound transducer and the acoustic impedance of tissue differ significantly. As a result, the ultrasound signal may experience significant reflection and divergence at the tissue/transducer interface. To address this issue, a tip or lens may be used as an interface between the transducer and tissue.
In common Doppler ultrasound applications, a tip material is selected to provide an optimum acoustic match between the ultrasonic transducer and tissue. This optimum acoustic match is the geometric mean impedance between the tissue and the transducer material, governed by the following equation.
Zoptimum=(Ztissue×Ztransducer)^½
Where Zoptimum is the desired acoustic impedance of the tip material; Ztissue is the acoustic impedance of tissue; and Ztranducer is the acoustic impedance of the transducer. Generally, Ztissue ranges from 1.38 MRayls (for fat) to 1.70 MRayls (for muscle), while Ztransducer is approximately 30 MRayls for ceramic transducer materials. Therefore, using Ztransducer of 1.54 MRayls (the average acoustic impedance for tissue) the desirable tip material should have an acoustic impedance around 6.79 MRayls.
Most materials having an acoustic impedance close to this range are made of epoxy composites and range from, for example, 1.78 MRayls for a methylpentene copolymer (e.g., TPX, Matsui Plastics, White Plains, N.Y.) to 4.39 MRayls for high temperature plastics (e.g., CELAZOLE, Curbell Plastics, Glenshaw, Pa.).
One drawback to using Doppler ultrasound devices for placing collateral openings in tissue is that conventional tip materials selected for their desirable acoustic impedance are not effective to deliver energy (e.g., RF, resistive heat, etc.) The acoustic impedance of electrically and thermally conductive materials is higher than the desired acoustic impedance of 6.79 MRayls. For example, Zaluminum is approximately 18 MRayls, Ztitanium is approximately 27 MRayls, and Zstainless steel is approximately 45 MRayls.
Another drawback to delivering energy through devices configured for Doppler applications is that the transducer is prone to being damaged. For example, when used to deliver therapeutic RF energy, an electrically conductive tip experiences heating. If a sufficient amount of heat is conducted from the tip, the transducer may depolarize. Moreover, conduction of heat through the device may adversely affect the joints and bonds between the transducer, tip and device. As a result, there is the potential of a catastrophic failure of the device if the assembly breaks apart during use in the body.
In view of the above, the present invention provides a device capable of locating an acceptable site for the creation of a collateral opening and then creating an opening in the tissue using a device capable of both functions. While the present invention is discussed as having applicability to creation of collateral openings it was found to have utility for other applications as well. For example, the present invention is suited for the application of energy to tissue in a safe manner (e.g., tumor ablation, tissue removal, application of heat to structures within the body, etc.). Especially when there is a need to avoid blood vessels, or other tissue/organs/structures. The invention has applicability given a need to use of Doppler effect to locate movement within tissue and then apply energy based on the observation of the Doppler effect.
Methods and devices for creating, and maintaining collateral channels are also discussed in U.S. patent application Ser. No. 09/633,651, filed on Aug. 7, 2000; U.S. patent application Ser. Nos. 09/947,144, 09/946,706, and 09/947,126 all filed on Sep. 4, 2001; U.S. Provisional Application No. 60/317,338 filed on Sep. 4, 2001, and 60/334,642 filed on Nov. 29, 2001, whereas the entirety of each listed application is incorporated by reference herein.
The invention related to devices for applying energy to tissue. The invention includes an elongate member having a proximal portion and a distal portion; a transducer assembly located towards the distal portion of the elongate member, and an electrically conductive tip located at a distal end of the elongate member adjacent to the transducer assembly and having a front and back surface, the back surface being in acoustical communication with the transducer assembly wherein the tip is adapted to communicate a source signal from the transducer assembly out through the front surface, the tip also being adapted to communicate a reflected signal from the front surface to the transducer; and at least two conducting members extending through at least a portion of the elongate member, at least one of the conducting members capable of electrically coupling an RF energy supply to the tip.
The tip of the device functions to direct signals to and from the transducer assembly as well as conduct electro-surgical energy (e.g., RF energy) to desired areas. As such, to accommodate the nature of electrically conductive materials so that they function as an acceptable Doppler tip, variations of the invention include tips that have a length selected from a multiple of one quarter of a wavelength of the source signal.
The invention further includes transducer assemblies wherein the transducer assembly comprises a covering having a proximal and distal end, at least one transducer having at least a first and second pole, at least a portion of the transducer being located within the covering, a first conductive medium in contact with the first pole of the transducer and extending to at least a portion of an outer surface of the covering, and wherein at least a first of the conducting members is electrically coupled to the first conductive medium, and a second of the conducting members extends through the proximal end of the covering and electrically couples to the second pole of the transducer.
The invention may include insulating layers that serve to protect tissue and/or parts of the device from unwanted heating. The elongate member of the device may also serve as the insulating layer or as additional insulation.
The invention also includes a transducer assembly that is configured to minimize the size of the device so that it may access deeper regions of the body (e.g., deeper regions of airways in the lungs). The transducer assembly may include a covering that is either conductive or is covered by a conductive medium. As such, the covering (or conductive medium) provides an electrical path to a pole of the transducer, thereby eliminating the need for a separate electrical connection. The conductive covering (or conductive medium) may optionally be used as an electrical path to a conductive tip.
The invention also includes a medical device for detecting Doppler shift and for applying energy to tissue, the medical device comprising an elongate member having a proximal portion and a distal portion; a transducer means (e.g., a transducer assembly as described herein) for generating a source signal and for receiving a reflected signal wherein the transducer means is located towards the distal portion of the elongate member; a directing means (e.g., a tip as described herein) for directing the source signal and the reflected signal, the signal directing means located at a distal end of the distal portion of the elongate member and being in acoustical communication with the transducer means, and a first conducting member and a second conducting member both extending through at least a portion of the elongate member, the conducting members electrically coupled to at least the transducer assembly.
The signal directing means described above may also be adapted to direct or deliver energy to tissue.
The invention also includes methods of locating a site to apply energy to tissue and applying energy to tissue. These methods include generating a source signal with a transducer, transmitting the source signal through an electrically conductive electrode to the tissue, receiving a reflected signal, determining any difference in frequency between the source signal and reflected signal, and applying energy to tissue using the electrically conductive electrode. In the present invention, the electrically conductive tip may serve as the electrically conductive electrode.
The methods include receiving the reflected signal through the electrically conductive electrode. The electrically conductive electrode may comprise a material selected from the group consisting of aluminum, titanium, stainless steel. Or, the electrically conductive electrode may comprise a non-electrically conductive material coated with an electrically conductive material.
The methods include generating the source signal using pulsed wave ultrasound. In such a case the source signal may have a pulse length equal to or less than (preferably half of) the time required for the reflected signal to return from a first area of interest.
The method includes determining any difference in frequency between the source signal and reflected signal starting at the time required for the reflected signal to return from the first area of interest and ending at the time required for the reflected signal to return from a second area of interest. In such cases, the first and second areas of interest may include the range of depth of penetration for determining the Doppler effect.
The invention includes kits containing the inventive device with any one or more of the following components, an RF energy supply, a Doppler ultrasound controller, a conduit as described in one or more of the applications listed herein, and a bronchoscope/endoscope.
Prior to considering the invention, simplified illustrations of various states of a natural airway and a blood gas interface found at a distal end of those airways are provided in
The following illustrations are examples of the invention described herein. It is contemplated that combinations of aspects of specific embodiments/variations or combinations of the specific embodiments/variations themselves are within the scope of this disclosure.
As will be explained in greater detail below, the production and maintenance of collateral openings or channels through airway walls permits expired air to pass directly out of the lung tissue and into the airways to ultimately facilitate exchange of oxygen into the blood and/or decompress hyper inflated lungs. The term ‘lung tissue’ is intended to include the tissue involved with gas exchange, including but not limited to, gas exchange membranes, alveolar walls, parenchyma and/or other such tissue. To accomplish the exchange of oxygen, the collateral channels allow fluid communication between an airway and lung tissue. Therefore, gaseous flow is improved within the lung by altering or redirecting the gaseous flow within the lung, or entirely within the lung.
In the following explanation of figures, similar numerals may represent similar features for the different variations of the invention. The invention herein is described by examples and a desired way of practicing the invention is described. However, the invention as claimed herein is not limited to that specific description in any manner. Equivalence to the description as hereinafter claimed is considered to be within the scope of protection of this patent.
The devices of the present invention are configured to locate a target site for creation of a collateral channel in the tissue and to create an opening in tissue. As discussed above, a benefit of this combination feature is that a single device is able to select a target location and then create an opening without having been moved. Although the device is discussed as being primarily used in the lungs, the device is not limited as such and it is contemplated that the invention has utility in other areas as well, specifically in applications in which blood vessels or other structures must be avoided while cutting or removing tissue (one such example is tumor removal.)
The present invention includes the use of a device which is able to detect the presence or absence of a blood vessel by placing a front portion of the device in contact with tissue. One variation of the invention includes the use of Doppler ultrasound to detect the presence of blood vessels within tissue. However, the frequency of the signals is not limited to the ultrasonic range, for example the frequency may be within the range of human hearing, etc.
The ultrasound Doppler operates at any frequency in the ultrasound range but preferably between 2 Mhz-30 Mhz. It is generally known that higher frequencies provide better resolution while lower frequencies offer better penetration of tissue. In the present invention, because location of blood vessels does not require actual imaging, there may be a balance obtained between the need for resolution and for penetration of tissue. Accordingly, an intermediate frequency may be used (e.g., around 8 Mhz). A variation of the invention may include inserting a fluid into the airway to provide a medium for the Doppler sensors to couple to the wall of the airway to detect blood vessels. In those cases where fluid is not inserted, the device may use mucus found within the airway to directly couple the sensor to the wall of the airway.
It is also contemplated that the inventive device may create openings in tissue using any type of energy capable of removing/ablating tissue. For example, either RF energy, or a focused ultrasound may be used.
The device 200 further includes a first conducting member 220 and a second conducting member 222 (e.g., wires) both extending through at least a portion of elongate member 218 to the transducer assembly 202. The conducting members 220, 222 may extend through a lumen of the elongate member 218 or may extend in the wall of the elongate member 218. In any case, the conducting members 220, 220 provide the energy and controls for the transducer assembly 202. For example, the conducting members 220, 222 may be coupled to an ultrasound source 190. Moreover, variations of the inventive device include conducting members 220, 222 which may be comprised of a series of wires, with one set of wires being coupled to respective poles of the transducer, and any number of additional sets of wires extending through the device. Ultimately, the wires enable the device to couple to energy and control units. Although not illustrated, the device 200 may also include an outer sheath (not shown in
Although the transducer assembly is adapted to generate a source signal and receive a reflected signal, variations of the invention may omit the transducer covering and other structures not necessary to generate a source signal and receive a reflected signal. Therefore, it is contemplated that the invention may simply have a transducer that is coupled to a controller.
The tip 204 is designed such that it interferes and redirects the signals in a desired direction in a manner like a lens. It also may be desirable to place an epoxy between the tip 204 and the transducer. Preferably, the epoxy is thin and applied without air gaps, bubbles or pockets. Also, the density/hardness of the epoxy should provide for transmission of the signal while minimizing any effect or change to the source signal. The configuration of the transducer assembly 202 permits the tip 204 to disperse a signal over a substantial portion of its outer surface 240. The tip 204 also is adapted to refract a reflected signal towards the transducer 208. Accordingly, given the above described configuration, the inventive device will be able to detect vessels with any part or substantially all of the lens 204 that contacts tissue.
Although the tip is of the present invention is able to transmit a source signal and receive a reflected signal, the invention is not limited to requiring both functions. For example, the inventive device could be configured to generate a source signal and direct the source signal to an area of interest but a second device or transducer assembly could be used to receive the reflected signal. Accordingly, a separate device could be used to generate the source signal with the inventive device being used to receive the reflected signal.
The invention contemplates the tip 204 as comprising an electrically conductive material such that energy (e.g., RF energy or thermal energy) may be delivered to the tissue via the tip 204. For example, the tip may comprise titanium, aluminum, or stainless steel, etc. any electrically conductive metal. Also, the tip 204 may be comprised of any material suitable for ultrasound applications but is not particularly electrically conductive. In such a case, the tip will have an electrically conductive coating about at least a portion of the tip. These tip materials include dimethyl pentene, a methylpentene copolymer (plastic-TPX), carbon aerogel, polycarbonate (e.g., Lexan), polystyrene, etc. (e.g., any standard material used for ultrasound applications.) Electrically conductive coatings include gold, silver, tantalum, copper, chrome, or any bio-compatible electrically conductive material, etc. This material may be coated, deposited, plated, painted, wound, wrapped (e.g., a conductive foil), etc. onto the tip 204.
As discussed above, traditional tip materials are selected to provide an optimum acoustic match between the ultrasonic transducer and tissue. Use of such electrically conductive materials do not provide optimum acoustic impedance in Doppler applications. To overcome the problem associated with tip materials having undesirable acoustic impedance, the tip 204 of the present invention is selected to be long enough to avoid excessive heating of the transducer 208 and at a length that minimizes the signal clutter resulting from the use of material.
In view of the above, a tip 204 length is selected in accordance with the following equation:
L=N(λ/4) for Ztransducer>Ztip>Ztissue
Where L=tip length; N=any integer; and λ=wavelength of the signal. It was found that the best performance was obtained by selecting a tip length where N is an odd integer. This minimizes the destructive interference of the signal caused by echoes reverberating within the tip. It was also found that while N=1 was acceptable for the Doppler function, the resulting tip length caused undesirable heating of the transducer. To achieve a balance of a tip length that would prevent unacceptable heating of the transducer, N was chosen to be 7 for one variation of the device. Accordingly, an acceptable length for a titanium tip corresponding to a frequency of 8 Mhz, equals 1.33 mm or 0.052 in.
A measurement of the tip lengths 242 may be seen in
As illustrated in
It may also be desirable that the device is configured such that there are no exposed sharp edges that may cause any unintended damage to tissue while the device is being used to determine the presence or absence of a blood vessel. In such a case, for example, the tip may be designed such that it doesn't have sharp edges, or any sharp edges may be covered by other parts of the device (e.g., the elongate member, an outer sheath, etc.)
As discussed herein, for some variations of the invention it is desirable to minimize the size of the device especially at the distal end. Although the invention may be any size, it was found that an overall device diameter of 0.071″ was acceptable. As noted, because the device is advanced through the airways, the device may treat deeper areas in the airways of the lungs given a smaller outside diameter of the distal end of the device. This size also permits delivery of the device into the lungs through the working channel of a standard bronchoscope or endoscope. However, this reduction in size is limited as functionality of the device may suffer. For example, one or more wires will be selected such that they will deliver sufficient RF energy over a desired period of time without experiencing unacceptable heating. Therefore, the smallest acceptable cross sectional area of a single wire or multiple wires will be a balance of the energy delivery requirements of the device versus the characteristics of the wire or wires.
The transducer or transducers may comprise a piezo-ceramic crystal (e.g., a Motorola PZT 3203 HD ceramic). In the current invention, a single-crystal piezo (SCP) is preferred, but the invention does not exclude the use of other types of ferroelectric material such as poly-crystalline ceramic piezos, polymer piezos, or polymer composites. The substrate, typically made from piezoelectric single crystals (SCP) or ceramics such as PZT, PLZT, PMN, PMN-PT; also, the crystal may be a multi layer composite of a ceramic piezoelectric material. Piezoelectric polymers such as PVDF may also be used. Micromachined transducers, such as those constructed on the surface of a silicon wafer are also contemplated (e.g., such as those provided by Sensant of San Leandro, Calif.) As described herein, the transducer or transducers used may be ceramic pieces coated with a conductive coating, such as gold. Other conductive coatings include sputtered metal, metals, or alloys, such as a member of the Platinum Group of the Periodic Table (Ru, Rh, Pd, Re, Os, Ir, and Pt) or gold. Titanium (Ti) is also especially suitable. The transducer may be further coated with a biocompatible layer such as Parylene or Parylene C.
The covering 206 of the transducer assembly 202 contains the transducer 208. In some variations of the invention, the covering 206 may comprise a conductive material. In such cases the covering 206 itself becomes part of the electrical path to the first pole of the transducer 208. Use of a conductive covering 206 may require insulating material 213 between the sides of the transducer 208, thereby permitting a first conductive medium 214 to electrically couple only one pole of the transducer 208 to the covering 206.
At least a portion of the front surface of the transducer 208, will be in contact with the conductive medium 214. The conductive medium 214 permits one of the poles of the transducer 208 to be placed in communication with a conducting member that is ultimately coupled to a power supply. As shown in this example, the conductive medium 214 places the pole of the transducer 208 in electrical communication with the covering 206. In some variations the conductive medium 214 may coat the entire transducer 208 and covering 206. Alternatively, the conductive medium 214 may be placed over an area small enough to allow for an electrical path between a conducting member and the respective pole of the transducer 208. The conductive medium 214 may be any conductive material (e.g., gold, silver, tantalum, copper, chrome, or any bio-compatible conductive material, etc. The material may be coated, deposited, plated, painted, wound, wrapped (e.g., a conductive foil), etc. onto the transducer assembly 202.
The transducer assembly 202 depicted in
When using a second conductive medium 254 to provide the energy supply to a conductive tip 204 it may be desirable to provide a conductive medium 254 of sufficient thickness so that the energy delivered to the tip 204 does not produce unwanted heating of the overall transducer assembly 202. As discussed above, conducting member(s) were sized to provide sufficient energy while minimizing heating of the member. In practice, the device used gold foils having a thickness ranging from 2-10 microns.
The inventive device is configured to communicate with an analyzing device or control unit 190 adapted to recognize the reflected signal or measure the Doppler shift between the signals. As mentioned above, the source signal may be reflected by changes in density between tissue. In such a case, the reflected signal will have the same frequency as the transmitted signal. When the source signal is reflected from blood moving within a vessel, the reflected signal has a different frequency than that of the source signal. This Doppler effect permits determination of the presence or absence of a blood vessel within tissue. The device may include a user interface which allows the user to determine the presence or absence of a blood vessel at the target site. Typically, the user interface provides an audible confirmation signal. However, the confirmation signal may be manifested in a variety of ways (e.g., light, graphically via a monitor/computer, etc.)
Although depicted as being external to the device 200, it is contemplated that the analyzing device 190 may alternatively be incorporated into the device 200. The transducer assembly of the invention is intended to include any transducer assembly that allows for the observation of Doppler effect, e.g., ultrasound, light, sound etc.
In variations of the invention using pulsed Doppler, the selection of the tip length, as discussed above, sets an important parameter for design of the Doppler pulse length and range gate so that excessive echo signal clutter caused by the use of titanium is reduced before the arrival of the echo signals from the area of interest.
The transmit pulse length is set to be less than the acoustic travel time for an echo signal from the area of tissue to be inspected. This setting allows the receiver to begin recovery from the transmit pulse before the first echo signal arrives at the transducer. As shown in
The values discussed herein are intended to serve as examples only with the underlying calculations being intended to show the methodology used for Doppler detection of blood vessels. For example, during trials it was found that an acceptable minimum and maximum depth of penetration of the device was 0.8 mm and 10 mm respectively. It is noted that depths are often measured as being normal to the surface of the tissue, and because the device will often approach the tissue at an angle to the surface of the tissue, the maximum and minimum ranges Rmax and Rmin used for determining the TOF are adjusted to reflect the normal distance from the tip of the device to the desired depth. (e.g., assuming a 60 degree angle of incidence, and a minimum and maximum depths of 0.8 mm and 10 mm, Rmin=0.92 mm and Rmax=11.55 mm.)
The time for a signal to travel from the tip to and from Rmin equals 2Rmin/Ctissue where Ctissue equals the speed of the signal in tissue (approximately 1540 m/s). The time for a signal to travel back and forth through the tip (assuming a 1.33 mm titanium tip, with Ctitanium=6100 m/s) was found to be 0.44 μs. Therefore, the time for the closest echoes of interest is approximately 1.2 μs plus 0.44 μs or 1.64 μs. The Transmit Pulse Length is then set to be less than time for the closest echoes of interest, preferably about ½ of 1.64 μs or ˜0.82 μs. Setting the Transmit Pulse Length to be less than the time for the closest echoes of interest allows the receiver to begin recovery from the reverberation of the transmit pulse in the titanium tip before the first echo signals arrives back at the transducer. As a result, the controller is configured to listen for the first Doppler echo signal starting at the earliest time the first echo signal will return. Based upon the above example, this time is 1.64 μs.
Using a combination of a gated gain control applied to the receiver and a gated carrier applied to the demodulator, the Doppler echo signals are thereafter received until a time that echoes return from the deepest area of interest (e.g., as noted above, 10 mm). This value is calculated based upon the TOF from the tip to the deepest area of interest (15 μs, calculated from 2Rmax/Ctissue.) plus the TOF through the tip (0.44 μs as discussed above.) Accordingly, Doppler signals from tissue of up to 1 cm of depth (Rmax) may be received up to 15.44 μs.
As illustrated, the timing control 281 supplies timing and control signals to the Doppler transmitter 282, the Doppler receiver 288, and the Doppler demodulator 290. The Doppler transmitter 282 amplifies an applied signal applied to generate a transmit pulse which is ultimately applied to the device 200. In one example, the transmit pulse, had a center frequency of 8 MHz and a pulse length of approximately 1 μs and an amplitude of 15 V peak. The transducer at the distal tip of the device 200 converts the transmit pulse into an acoustic pulse. As the acoustic pulse travels through the tissue and blood the structures and cells produce reflections that travel back toward the probe tip and there converted from acoustic echoes to electrical echo signals 287. These echo signals 287 consist of a mixture of signals, some of a frequency equal to that of the transmitted signal (echoes from stationary structures in the ultrasonic field), and some echoes that are shifted in frequency by the Doppler effect. The echo signals 287 are amplified by the Doppler receiver 288. A gated gain control 284 is set to start increasing gain after the transmit pulse ends but soon enough for echo signals 287 of interest to be amplified. The gated gain control 284 lasts until echo signals 287 from the deepest structures of interest have been amplified. These echo signals 287 are demodulated in the Doppler demodulator 290 using a gated carrier 285 in order to produce demodulated echo signals 291 that contain Doppler signals from moving blood cells at audio frequencies. The demodulated echo signals 291 are then filtered and amplified by the Doppler audio processor 292 to improve the signal fidelity of the Doppler audio signals. These filtered and amplified signals are then sent to the Audio Speaker 293.
It is also noted that the device may also designed to have a double shield. First, the twisted pair wires connecting the transducer assembly to the Doppler control unit 190 will be shielded. Furthermore, because the energy supply 188 may be delivered through one of the pair of wires, the outer portion of the catheter that is exposed proximal to the working channel of an endoscope will also be shielded to prevent undesirable conduction of current.
Number | Name | Date | Kind |
---|---|---|---|
2127903 | Bowen | Aug 1938 | A |
3174851 | Buehler et al. | Mar 1965 | A |
3351463 | Rozner et al. | Nov 1967 | A |
3433226 | Boyd | Mar 1969 | A |
3556079 | Omizo | Jan 1971 | A |
3565062 | Kuris | Feb 1971 | A |
3617060 | Leggi | Nov 1971 | A |
3753700 | Harrison et al. | Aug 1973 | A |
3779234 | Eggleton et al. | Dec 1973 | A |
3823717 | Pohlman et al. | Jul 1974 | A |
3942530 | Northeved | Mar 1976 | A |
4249539 | Vilkomerson et al. | Feb 1981 | A |
4249541 | Pratt | Feb 1981 | A |
4319580 | Colley et al. | Mar 1982 | A |
4355426 | MacGregor | Oct 1982 | A |
4407294 | Vilkomerson | Oct 1983 | A |
4431006 | Trimmer et al. | Feb 1984 | A |
4503569 | Dotter | Mar 1985 | A |
4534761 | Raible | Aug 1985 | A |
4538618 | Rosenberg et al. | Sep 1985 | A |
4582067 | Silverstein et al. | Apr 1986 | A |
4583969 | Mortensen | Apr 1986 | A |
4658817 | Hardy | Apr 1987 | A |
4674498 | Stasz | Jun 1987 | A |
4676782 | Yamamoto et al. | Jun 1987 | A |
4682596 | Bales et al. | Jul 1987 | A |
4687482 | Hanson | Aug 1987 | A |
4750902 | Wuchinich et al. | Jun 1988 | A |
4753236 | Healey | Jun 1988 | A |
4757821 | Snyder | Jul 1988 | A |
4757822 | Di Giuliomaria et al. | Jul 1988 | A |
4769031 | McGough | Sep 1988 | A |
4770185 | Silverstein et al. | Sep 1988 | A |
4771788 | Millar | Sep 1988 | A |
4773413 | Hussein et al. | Sep 1988 | A |
4785402 | Matsuo et al. | Nov 1988 | A |
4795465 | Marten | Jan 1989 | A |
4802476 | Noerenberg et al. | Feb 1989 | A |
4807634 | Enjoji et al. | Feb 1989 | A |
4808153 | Parisi | Feb 1989 | A |
4834102 | Schwarzchild et al. | May 1989 | A |
4869268 | Yoon | Sep 1989 | A |
4870953 | DonMicheal et al. | Oct 1989 | A |
4887606 | Yock et al. | Dec 1989 | A |
4892098 | Sauer | Jan 1990 | A |
4899757 | Pope, Jr. et al. | Feb 1990 | A |
4917097 | Proudian, et al. | Apr 1990 | A |
4920954 | Alliger et al. | May 1990 | A |
4924863 | Sterzer | May 1990 | A |
4936281 | Stasz | Jun 1990 | A |
4957508 | Kaneko et al. | Sep 1990 | A |
4967753 | Haase et al. | Nov 1990 | A |
4973301 | Nissenkorn | Nov 1990 | A |
4977898 | Schwarzschild et al. | Dec 1990 | A |
5002058 | Martinelli | Mar 1991 | A |
5030201 | Palestrant | Jul 1991 | A |
5042981 | Gross | Aug 1991 | A |
5054483 | Marten et al. | Oct 1991 | A |
5061275 | Wallstén et al. | Oct 1991 | A |
5064435 | Porter | Nov 1991 | A |
5069664 | Suess et al. | Dec 1991 | A |
5081993 | Kitney et al. | Jan 1992 | A |
5100423 | Fearnot | Mar 1992 | A |
5105816 | Shimura et al. | Apr 1992 | A |
5105817 | Uchibori et al. | Apr 1992 | A |
5125926 | Linhares et al. | Jun 1992 | A |
5127917 | Niederhauser et al. | Jul 1992 | A |
5131394 | Gehlbach | Jul 1992 | A |
5148809 | Biegeleisen-Knight et al. | Sep 1992 | A |
5170793 | Takano et al. | Dec 1992 | A |
5190528 | Fonger et al. | Mar 1993 | A |
5201316 | Pomeranz et al. | Apr 1993 | A |
5209721 | Wilk | May 1993 | A |
5226421 | Frisbie et al. | Jul 1993 | A |
5238027 | Lee | Aug 1993 | A |
5254112 | Sinofsky et al. | Oct 1993 | A |
5257990 | Nash | Nov 1993 | A |
5259385 | Miller et al. | Nov 1993 | A |
5261409 | Dardel | Nov 1993 | A |
5269326 | Verrier | Dec 1993 | A |
5273529 | Idowu | Dec 1993 | A |
5275166 | Vaitekunas et al. | Jan 1994 | A |
5282824 | Gianturco | Feb 1994 | A |
5287861 | Wilk | Feb 1994 | A |
5295484 | Marcus et al. | Mar 1994 | A |
5299578 | Rotteveel et al. | Apr 1994 | A |
5309915 | Ember | May 1994 | A |
5311871 | Yock | May 1994 | A |
5313950 | Ishikawa et al. | May 1994 | A |
5316001 | Ferek-Petric et al. | May 1994 | A |
5320106 | Tanaka | Jun 1994 | A |
5330500 | Song | Jul 1994 | A |
5334183 | Wuchinich | Aug 1994 | A |
5334210 | Gianturco | Aug 1994 | A |
5339289 | Erickson | Aug 1994 | A |
5344420 | Hilal et al. | Sep 1994 | A |
5351693 | Taimisto et al. | Oct 1994 | A |
5363852 | Sharkawy | Nov 1994 | A |
5363853 | Lieber et al. | Nov 1994 | A |
5368035 | Hamm et al. | Nov 1994 | A |
5372138 | Crowley et al. | Dec 1994 | A |
5375602 | Lancee et al. | Dec 1994 | A |
5377682 | Ueno et al. | Jan 1995 | A |
5380316 | Aita et al. | Jan 1995 | A |
5381795 | Nordgren et al. | Jan 1995 | A |
5383460 | Jang et al. | Jan 1995 | A |
5383887 | Nadal | Jan 1995 | A |
5385148 | Lesh et al. | Jan 1995 | A |
5389096 | Aita et al. | Feb 1995 | A |
5402792 | Kimura | Apr 1995 | A |
5409012 | Sahatjian | Apr 1995 | A |
5409019 | Wilk | Apr 1995 | A |
5411466 | Hess | May 1995 | A |
5413601 | Keshelava | May 1995 | A |
5425739 | Jessen | Jun 1995 | A |
5427107 | Milo et al. | Jun 1995 | A |
5429144 | Wilk | Jul 1995 | A |
5435314 | Dias | Jul 1995 | A |
5452733 | Sterman et al. | Sep 1995 | A |
5454373 | Koger et al. | Oct 1995 | A |
5454809 | Janssen | Oct 1995 | A |
5456258 | Kondo et al. | Oct 1995 | A |
5458120 | Lorraine | Oct 1995 | A |
5464016 | Nicholas et al. | Nov 1995 | A |
5465726 | Dickinson et al. | Nov 1995 | A |
5466242 | Mori | Nov 1995 | A |
5470308 | Edwards et al. | Nov 1995 | A |
5474075 | Goldberg et al. | Dec 1995 | A |
5484416 | Gittings | Jan 1996 | A |
5485841 | Watkin et al. | Jan 1996 | A |
5500012 | Brucker et al. | Mar 1996 | A |
5505088 | Chandraratna et al. | Apr 1996 | A |
5514154 | Lau et al. | May 1996 | A |
5520684 | Imran | May 1996 | A |
5522822 | Phelps et al. | Jun 1996 | A |
5527292 | Adams et al. | Jun 1996 | A |
5527324 | Krantz et al. | Jun 1996 | A |
5540713 | Schnepp-Pesch et al. | Jul 1996 | A |
5545195 | Lennox et al. | Aug 1996 | A |
5545210 | Hess et al. | Aug 1996 | A |
5554118 | Jang | Sep 1996 | A |
5554152 | Aita et al. | Sep 1996 | A |
5555886 | Weng et al. | Sep 1996 | A |
5564434 | Halperin et al. | Oct 1996 | A |
5571086 | Kaplan et al. | Nov 1996 | A |
5571180 | Blom | Nov 1996 | A |
5573531 | Gregory | Nov 1996 | A |
5575818 | Pinchuk | Nov 1996 | A |
5588432 | Crowley | Dec 1996 | A |
5593417 | Rhodes | Jan 1997 | A |
5596989 | Morita | Jan 1997 | A |
5607444 | Lam | Mar 1997 | A |
5615679 | Ri et al. | Apr 1997 | A |
5618301 | Hauenstein et al. | Apr 1997 | A |
5630837 | Crowley | May 1997 | A |
D380266 | Boatman et al. | Jun 1997 | S |
5645559 | Hachtman et al. | Jul 1997 | A |
5647871 | Levine et al. | Jul 1997 | A |
5653746 | Schmitt | Aug 1997 | A |
5655548 | Nelson et al. | Aug 1997 | A |
5658279 | Nardella et al. | Aug 1997 | A |
5658280 | Issa | Aug 1997 | A |
5672172 | Zupkas | Sep 1997 | A |
5674277 | Freitag | Oct 1997 | A |
5674298 | Levy et al. | Oct 1997 | A |
5678555 | O'Connell | Oct 1997 | A |
5693085 | Buirge et al. | Dec 1997 | A |
5704361 | Seward et al. | Jan 1998 | A |
5713949 | Jayaraman | Feb 1998 | A |
5716393 | Lindenberg et al. | Feb 1998 | A |
5718701 | Shai et al. | Feb 1998 | A |
5720735 | Dorros | Feb 1998 | A |
5725547 | Chuter | Mar 1998 | A |
5736642 | Yost et al. | Apr 1998 | A |
5741234 | Aboul-Hosn | Apr 1998 | A |
5741333 | Frid | Apr 1998 | A |
5752518 | McGee et al. | May 1998 | A |
5755769 | Richard et al. | May 1998 | A |
5755778 | Kleshinski | May 1998 | A |
5759769 | Sia et al. | Jun 1998 | A |
5779642 | Nightengale | Jul 1998 | A |
5792119 | Marx | Aug 1998 | A |
5795325 | Valley et al. | Aug 1998 | A |
5797920 | Kim | Aug 1998 | A |
5810008 | Dekel et al. | Sep 1998 | A |
5810836 | Hussein et al. | Sep 1998 | A |
5824046 | Smith et al. | Oct 1998 | A |
5830191 | Hildwein et al. | Nov 1998 | A |
5830222 | Makower | Nov 1998 | A |
5840431 | Kall | Nov 1998 | A |
5843175 | Frantzen | Dec 1998 | A |
5846205 | Curley et al. | Dec 1998 | A |
5849037 | Frid | Dec 1998 | A |
5855597 | Jayaraman | Jan 1999 | A |
5860920 | McGee et al. | Jan 1999 | A |
5860951 | Eggers et al. | Jan 1999 | A |
5868763 | Spence et al. | Feb 1999 | A |
5876345 | Eaton et al. | Mar 1999 | A |
5876434 | Flomenblit et al. | Mar 1999 | A |
5876448 | Thompson et al. | Mar 1999 | A |
5885219 | Nightengale | Mar 1999 | A |
5916158 | Webster, Jr. | Jun 1999 | A |
5921995 | Kleshinski | Jul 1999 | A |
5922019 | Hankh et al. | Jul 1999 | A |
5935135 | Bramfitt et al. | Aug 1999 | A |
5938697 | Killion et al. | Aug 1999 | A |
5951567 | Javier, Jr. et al. | Sep 1999 | A |
5954649 | Chia et al. | Sep 1999 | A |
5957849 | Munro | Sep 1999 | A |
5957919 | Laufer | Sep 1999 | A |
5957974 | Thompson et al. | Sep 1999 | A |
5967990 | Thierman et al. | Oct 1999 | A |
5968053 | Revelas | Oct 1999 | A |
5968070 | Bley et al. | Oct 1999 | A |
5971980 | Sherman | Oct 1999 | A |
5972017 | Berg et al. | Oct 1999 | A |
5976178 | Goldsteen et al. | Nov 1999 | A |
5984871 | TenHoff et al. | Nov 1999 | A |
5993484 | Shmulewitz | Nov 1999 | A |
6001124 | Bachinski | Dec 1999 | A |
6002955 | Willems et al. | Dec 1999 | A |
6003517 | Sheffield et al. | Dec 1999 | A |
6004269 | Crowley et al. | Dec 1999 | A |
6004273 | Sakamoto et al. | Dec 1999 | A |
6004319 | Gobel et al. | Dec 1999 | A |
6007544 | Kim | Dec 1999 | A |
6007574 | Pulnev et al. | Dec 1999 | A |
6010529 | Herweck et al. | Jan 2000 | A |
6011995 | Guglielmi et al. | Jan 2000 | A |
6013033 | Berger et al. | Jan 2000 | A |
6013093 | Nott et al. | Jan 2000 | A |
6013854 | Moriuchi | Jan 2000 | A |
6015405 | Schwartz et al. | Jan 2000 | A |
6019787 | Richard et al. | Feb 2000 | A |
6022371 | Killion et al. | Feb 2000 | A |
6024703 | Zanelli et al. | Feb 2000 | A |
6030392 | Dakov | Feb 2000 | A |
6032674 | Eggers et al. | Mar 2000 | A |
6036702 | Bachinski et al. | Mar 2000 | A |
6045511 | Ott et al. | Apr 2000 | A |
6045532 | Eggers et al. | Apr 2000 | A |
6048362 | Berg | Apr 2000 | A |
6053941 | Lindenberg et al. | Apr 2000 | A |
6059731 | Seward et al. | May 2000 | A |
6059811 | Pinchasik et al. | May 2000 | A |
6063111 | Hieshima et al. | May 2000 | A |
6064902 | Haissaguerre et al. | May 2000 | A |
6068638 | Makower | May 2000 | A |
6070094 | Swanson et al. | May 2000 | A |
6074349 | Crowley | Jun 2000 | A |
6074416 | Berg et al. | Jun 2000 | A |
6080109 | Baker et al. | Jun 2000 | A |
6096053 | Bates | Aug 2000 | A |
6112123 | Kelleher et al. | Aug 2000 | A |
6113612 | Swanson et al. | Sep 2000 | A |
6117101 | Diederich et al. | Sep 2000 | A |
6120432 | Sullivan et al. | Sep 2000 | A |
6129726 | Edwards et al. | Oct 2000 | A |
6135997 | Laufer et al. | Oct 2000 | A |
6143019 | Motamedi et al. | Nov 2000 | A |
6152937 | Peterson et al. | Nov 2000 | A |
6152945 | Bachinski et al. | Nov 2000 | A |
6159225 | Makower | Dec 2000 | A |
6162245 | Jayaraman | Dec 2000 | A |
6165127 | Crowley | Dec 2000 | A |
6174323 | Biggs et al. | Jan 2001 | B1 |
6183444 | Glines et al. | Feb 2001 | B1 |
6186942 | Sullivan et al. | Feb 2001 | B1 |
6190353 | Makower et al. | Feb 2001 | B1 |
6200313 | Abe et al. | Mar 2001 | B1 |
6206831 | Suorsa et al. | Mar 2001 | B1 |
6231587 | Makower | May 2001 | B1 |
6235024 | Tu | May 2001 | B1 |
6235054 | Berg et al. | May 2001 | B1 |
6241742 | Spence et al. | Jun 2001 | B1 |
6241746 | Bosma et al. | Jun 2001 | B1 |
6245020 | Moore et al. | Jun 2001 | B1 |
6245102 | Jayaraman | Jun 2001 | B1 |
6258100 | Alferness et al. | Jul 2001 | B1 |
6258115 | Dubrul | Jul 2001 | B1 |
6270524 | Kim | Aug 2001 | B1 |
6280457 | Wallace et al. | Aug 2001 | B1 |
6283951 | Flaherty et al. | Sep 2001 | B1 |
6283983 | Makower et al. | Sep 2001 | B1 |
6287290 | Perkins et al. | Sep 2001 | B1 |
6290728 | Phelps et al. | Sep 2001 | B1 |
6293951 | Alferness et al. | Sep 2001 | B1 |
6299635 | Frantzen | Oct 2001 | B1 |
6309375 | Glines et al. | Oct 2001 | B1 |
6309416 | Swanson et al. | Oct 2001 | B1 |
6328689 | Gonzalez et al. | Dec 2001 | B1 |
6336933 | Parodi | Jan 2002 | B1 |
6344053 | Boneau | Feb 2002 | B1 |
6371964 | Vargas et al. | Apr 2002 | B1 |
6394956 | Chandrasekaran et al. | May 2002 | B1 |
6428550 | Vargas et al. | Aug 2002 | B1 |
6440163 | Swanson et al. | Aug 2002 | B1 |
6488673 | Laufer et al. | Dec 2002 | B1 |
6490474 | Willis et al. | Dec 2002 | B1 |
6514249 | Maguire | Feb 2003 | B1 |
6514290 | Loomas | Feb 2003 | B1 |
6533812 | Swanson et al. | Mar 2003 | B2 |
6585655 | Crowley | Jul 2003 | B2 |
6599311 | Biggs et al. | Jul 2003 | B1 |
6616675 | Evard et al. | Sep 2003 | B1 |
6623437 | Hinchliffe et al. | Sep 2003 | B2 |
6629951 | Laufer et al. | Oct 2003 | B2 |
6634363 | Danek et al. | Oct 2003 | B1 |
6692494 | Cooper et al. | Feb 2004 | B1 |
6712804 | Roue et al. | Mar 2004 | B2 |
6749606 | Keast et al. | Jun 2004 | B2 |
6770070 | Balbierz | Aug 2004 | B1 |
6970733 | Willis et al. | Nov 2005 | B2 |
6997189 | Biggs et al. | Feb 2006 | B2 |
7175644 | Cooper et al. | Feb 2007 | B2 |
20010007940 | Hosheng et al. | Jul 2001 | A1 |
20010021872 | Bailey et al. | Sep 2001 | A1 |
20010047180 | Grudem et al. | Nov 2001 | A1 |
20020002401 | McGuckin, Jr. et al. | Jan 2002 | A1 |
20020022833 | Maguire et al. | Feb 2002 | A1 |
20020042564 | Cooper et al. | Apr 2002 | A1 |
20020042566 | Cooper et al. | Apr 2002 | A1 |
20020055772 | McGuckin, Jr. et al. | May 2002 | A1 |
20020087153 | Roschak et al. | Jul 2002 | A1 |
20020111619 | Keast et al. | Aug 2002 | A1 |
20020111620 | Cooper et al. | Aug 2002 | A1 |
20020128647 | Roschak | Sep 2002 | A1 |
20020138074 | Keast et al. | Sep 2002 | A1 |
20030070676 | Cooper et al. | Apr 2003 | A1 |
20030130657 | Tom et al. | Jul 2003 | A1 |
20040073155 | Laufer et al. | Apr 2004 | A1 |
20040073201 | Cooper | Apr 2004 | A1 |
20040211434 | Loomas et al. | Oct 2004 | A1 |
20040220556 | Cooper et al. | Nov 2004 | A1 |
20050043751 | Phan et al. | Feb 2005 | A1 |
20050043752 | Phan et al. | Feb 2005 | A1 |
20050049615 | Cooper et al. | Mar 2005 | A1 |
20050056292 | Cooper | Mar 2005 | A1 |
20050060041 | Phan et al. | Mar 2005 | A1 |
20050060042 | Phan et al. | Mar 2005 | A1 |
20050060044 | Roschak | Mar 2005 | A1 |
20050085801 | Cooper et al. | Apr 2005 | A1 |
20050096529 | Cooper et al. | May 2005 | A1 |
20050107783 | Tom et al. | May 2005 | A1 |
20050137518 | Biggs et al. | Jun 2005 | A1 |
20050137611 | Escudero et al. | Jun 2005 | A1 |
20050137712 | Biggs et al. | Jun 2005 | A1 |
20050137715 | Phan et al. | Jun 2005 | A1 |
20050171527 | Bhola | Aug 2005 | A1 |
20050177144 | Phan et al. | Aug 2005 | A1 |
20050182475 | Jen et al. | Aug 2005 | A1 |
20050192526 | Biggs et al. | Sep 2005 | A1 |
20050228268 | Cole | Oct 2005 | A1 |
20060116749 | Willink et al. | Jun 2006 | A1 |
20060135984 | Kramer et al. | Jun 2006 | A1 |
20060142672 | Keast et al. | Jun 2006 | A1 |
20060276807 | Keast et al. | Dec 2006 | A1 |
20060280772 | Roschak et al. | Dec 2006 | A1 |
20060280773 | Roschak et al. | Dec 2006 | A1 |
20070123922 | Cooper et al. | May 2007 | A1 |
Number | Date | Country |
---|---|---|
3821836 | Jan 1990 | DE |
0347098 | Dec 1989 | EP |
0443256 | Aug 1991 | EP |
2000-107178 | Apr 2000 | JP |
2001-104315 | Apr 2001 | JP |
WO 8906515 | Jul 1989 | WO |
WO 9001300 | Feb 1990 | WO |
WO 9502361 | Jan 1995 | WO |
WO 9639914 | Dec 1996 | WO |
WO 9717014 | May 1997 | WO |
WO 9717105 | May 1997 | WO |
WO 9816161 | Apr 1998 | WO |
WO 9828035 | Jul 1998 | WO |
WO 9848706 | Nov 1998 | WO |
WO 9901076 | Jan 1999 | WO |
WO 9911182 | Mar 1999 | WO |
WO 9925419 | May 1999 | WO |
WO 9960953 | Dec 1999 | WO |
WO 0067825 | Nov 2000 | WO |
WO 0072908 | Dec 2000 | WO |
WO 0113839 | Mar 2001 | WO |
WO 0128433 | Apr 2001 | WO |
WO 0132088 | May 2001 | WO |
WO 0170117 | Sep 2001 | WO |
WO 0200278 | Jan 2002 | WO |
Number | Date | Country | |
---|---|---|---|
20020128647 A1 | Sep 2002 | US |
Number | Date | Country | |
---|---|---|---|
60269130 | Feb 2001 | US | |
60176141 | Jan 2000 | US | |
60147528 | Aug 1999 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09633651 | Aug 2000 | US |
Child | 09908087 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09946706 | Sep 2001 | US |
Child | 10080344 | US | |
Parent | 09908087 | Jul 2001 | US |
Child | 09946706 | US |